Senescent CD8+ T cells impair CAR T therapy by reducing cell growth, migration, and tumor killing, with gene signatures ...

Children's Hospital of Philadelphia Pathology and Laboratory Medicine researchers uncovered how killer T cells – called CD8+ T cells – keep fighting inside tumors, where nutrients are scarce and ...

Intralesional nivolumab seems effective for reducing the size of precancerous oral lesions, according to a study presented at the annual meeting of the American Association for Cancer Research, held ...

Short-term nutritional state can reshape T cell metabolism, with post-meal lipid metabolism enhancing T cell metabolic ...

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the ...

Yale researchers have identified CD8+ T cells as a key driver of kidney damage in lupus, challenging the long-standing focus on B cells. The discovery may explain why some patients do not respond to ...

Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...

Factor Bioscience Inc., a Cambridge-based biotechnology company focused on using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today announced its participation ...

Detailed price information for Biovaxys Technology Corp (BIOV-CN) from The Globe and Mail including charting and trades.